Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.10.18
Views: 1868

Dr Laura Bonanno - University of Padova, Padova, Italy

Dr Laura Bonanno speaks with ecancer at ESMO 2018 in Munich about results from a study on using liquid biopsy as a tool to monitor and predict clinical benefit from chemotherapy and immunotherapy in aNSCLC.

Dr Bonanno states that it was possible to predict the benefit from the systemic treatment at early time points.

For more lung cancer news from the conference, watch Dr Enriqueta Felip summarise her highlights.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation